PT  - JOURNAL ARTICLE
AU  - Plewa, Cherylene
TI  - Application of Lentiviral Vectors for Development of Production Cell Lines and Safety Testing of Lentiviral-Derived Cells or Products
DP  - 2010 Sep 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - 386--391
VI  - 64
IP  - 5
4099  - http://journal.pda.org/content/64/5/386.short
4100  - http://journal.pda.org/content/64/5/386.full
SO  - PDA J Pharm Sci Technol2010 Sep 01; 64
AB  - Lentiviral vectors (LVs) are frequently used to engineer cell lines for preclinical research purposes including assay development and target validation. Development of production cell lines for manufacturing recombinant protein therapeutics may also benefit from the use of LVs because they may reduce timelines and generate more uniform or higher expressing stable pools and clones. In addition, LVs could be advantageous for engineering new, alternative host cell substrates due to their ability to efficiently transduce most cell types. We demonstrate here that NS0 mouse myeloma cells, a host cell frequently used for protein production, can be transduced with LVs to greater than 80% efficiency and with no cytotoxic effects. The use of LVs for engineering of production cell lines will require additional testing procedures. Since LVs have previously been used in human gene therapy clinical trials, safety testing assays and procedures have been developed that could easily be applied to the development process for manufacturing cell lines to ensure the absence of unwanted viral material in cell banks and biologic products.